C4 THERAPEUTICS INC's ticker is CCCC and the CUSIP is 12529R107. A total of 120 filers reported holding C4 THERAPEUTICS INC in Q1 2023. The put-call ratio across all filers is 0.07 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $621 | -27.4% | 334 | +7.4% | 0.00% | – |
| Q2 2023 | $855 | -96.4% | 311 | -95.8% | 0.00% | – |
| Q1 2023 | $23,509 | -56.5% | 7,487 | +20.6% | 0.00% | – |
| Q3 2022 | $54,000 | +1250.0% | 6,209 | +1136.9% | 0.00% | – |
| Q2 2022 | $4,000 | -99.1% | 502 | -97.3% | 0.00% | – |
| Q1 2022 | $456,000 | -54.6% | 18,784 | -39.8% | 0.00% | – |
| Q4 2021 | $1,005,000 | -20.8% | 31,228 | +10.1% | 0.00% | – |
| Q3 2021 | $1,269,000 | – | 28,376 | +80974.3% | 0.00% | – |
| Q2 2021 | $0 | -100.0% | 35 | -99.3% | 0.00% | – |
| Q1 2021 | $195,000 | -84.7% | 5,279 | -86.3% | 0.00% | – |
| Q4 2020 | $1,277,000 | – | 38,527 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| COMMODORE CAPITAL LP | 481,094 | $15,939,000 | 8.67% |
| Bain Capital Life Sciences Investors, LLC | 1,642,209 | $54,406,000 | 3.42% |
| Darwin Global Management, Ltd. | 228,595 | $7,573,000 | 2.11% |
| Asymmetry Capital Management, L.P. | 139,343 | $4,616,000 | 2.10% |
| Cormorant Asset Management, LP | 2,490,065 | $80,021,000 | 1.90% |
| Logos Global Management LP | 477,928 | $15,834,000 | 1.36% |
| SPHERA FUNDS MANAGEMENT LTD. | 443,824 | $14,601,000 | 1.30% |
| Soleus Capital Management, L.P. | 268,548 | $8,897,000 | 1.17% |
| P.A.W. CAPITAL CORP | 40,000 | $1,325,000 | 1.17% |
| RTW INVESTMENTS, LP | 2,149,228 | $68,679,000 | 1.15% |